Sutro Biopharma GAAP EPS of -$2.96 misses by $0.06, revenue of $62.04M beats by $2.84M

Stock Information for Sutro Biopharma Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Sutro Biopharma Inc.

Smart Money Abandons Single-Asset Risk: Why Platforms Now Command 60% of Pharma Pipelines
Sutro Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sutro Biopharma Announces First Cohort of Patients Dosed in Phase 1 Trial of STRO-004, a Next-Generation Tissue Factor ADC, in TF-Expressing Solid Tumors
Sutro Biopharma Announces 1-for-10 Reverse Stock Split
Sutro Biopharma Highlights Next-Generation ADC Innovation at Virtual R&D Day
Sutro Biopharma Reports Third Quarter 2025 Financial Results and Business Highlights
Sutro Biopharma to Host Virtual Research & Development Day on November 12, 2025

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.